On Thursday, Twist Bioscience got an upgrade to its Relative Strength (RS) Rating, from 76 to 81.
IBD's proprietary rating tracks price movement with a 1 (worst) to 99 (best) score. The score shows how a stock's price behavior over the last 52 weeks compares to all the other stocks in our database.
Decades of market research reveals that the market's biggest winners tend to have an 80 or better RS Rating in the early stages of their moves.
Risk Management In The Stock Market: How Much Money To Invest Now
Twist Bioscience has climbed more than 5% past a 43.21 entry in a first-stage cup without handle, meaning it's now out of a proper buy zone. Look for the stock to create a new chance to pick up shares like a three-weeks tight or pullback to the 50-day or 10-week line.
The company showed 0% earnings growth last quarter. Revenue increased 24%.
The company holds the No. 99 rank among its peers in the Medical-Biomed/Biotech industry group. Corcept Therapeutics, Catalyst Pharmaceuticals and United Therapeutics are among the top 5 highly rated stocks within the group.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
Stocks With Rising Relative Strength Ratings
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
